NO332025B1 - Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter - Google Patents
Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter Download PDFInfo
- Publication number
- NO332025B1 NO332025B1 NO20024980A NO20024980A NO332025B1 NO 332025 B1 NO332025 B1 NO 332025B1 NO 20024980 A NO20024980 A NO 20024980A NO 20024980 A NO20024980 A NO 20024980A NO 332025 B1 NO332025 B1 NO 332025B1
- Authority
- NO
- Norway
- Prior art keywords
- particles
- weight
- powder according
- particle size
- mixture
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 47
- 239000008188 pellet Substances 0.000 title description 24
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 154
- 239000004480 active ingredient Substances 0.000 claims abstract description 44
- 239000010419 fine particle Substances 0.000 claims abstract description 33
- 239000002245 particle Substances 0.000 claims description 192
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 100
- 235000019359 magnesium stearate Nutrition 0.000 claims description 50
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 27
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 10
- 229960004436 budesonide Drugs 0.000 claims description 10
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 7
- 229960002848 formoterol Drugs 0.000 claims description 7
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 6
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011362 coarse particle Substances 0.000 claims description 3
- 229940112141 dry powder inhaler Drugs 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 238000005336 cracking Methods 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 67
- 210000002345 respiratory system Anatomy 0.000 abstract description 6
- 208000019693 Lung disease Diseases 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 230000009969 flowable effect Effects 0.000 abstract description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 39
- 238000002156 mixing Methods 0.000 description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 26
- 229960001375 lactose Drugs 0.000 description 26
- 239000008101 lactose Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 239000000443 aerosol Substances 0.000 description 17
- 239000013020 final formulation Substances 0.000 description 17
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 15
- 229960000193 formoterol fumarate Drugs 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- 238000009826 distribution Methods 0.000 description 14
- 239000000654 additive Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000004570 mortar (masonry) Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 238000005563 spheronization Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000010422 painting Methods 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- -1 8-hydroxy-2(1H)-quinolinon-5-yl Chemical group 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005280 amorphization Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0009469.8A GB0009469D0 (en) | 2000-04-17 | 2000-04-17 | Improvements in or relating to formalities for use in inhaler devices |
| EP00113608 | 2000-06-27 | ||
| PCT/EP2001/004338 WO2001078693A2 (en) | 2000-04-17 | 2001-04-17 | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20024980D0 NO20024980D0 (no) | 2002-10-16 |
| NO20024980L NO20024980L (no) | 2002-12-17 |
| NO332025B1 true NO332025B1 (no) | 2012-05-29 |
Family
ID=26071084
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024980A NO332025B1 (no) | 2000-04-17 | 2002-10-16 | Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter |
| NO20024971A NO20024971L (no) | 2000-04-17 | 2002-10-16 | Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger |
| NO20024973A NO342999B1 (no) | 2000-04-17 | 2002-10-16 | Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav |
| NO20110885A NO336687B1 (no) | 2000-04-17 | 2011-06-20 | Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024971A NO20024971L (no) | 2000-04-17 | 2002-10-16 | Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger |
| NO20024973A NO342999B1 (no) | 2000-04-17 | 2002-10-16 | Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav |
| NO20110885A NO336687B1 (no) | 2000-04-17 | 2011-06-20 | Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US8182791B2 (cs) |
| EP (6) | EP1274406B1 (cs) |
| JP (2) | JP2003530425A (cs) |
| KR (1) | KR20030069047A (cs) |
| CN (1) | CN1424909A (cs) |
| AT (5) | ATE513542T1 (cs) |
| AU (3) | AU2001258343A1 (cs) |
| BR (3) | BR0110139A (cs) |
| CA (3) | CA2406201C (cs) |
| CY (1) | CY1107315T1 (cs) |
| CZ (1) | CZ301904B6 (cs) |
| DE (3) | DE60131265T2 (cs) |
| DK (3) | DK1274406T3 (cs) |
| DZ (1) | DZ3315A1 (cs) |
| EE (1) | EE05257B1 (cs) |
| ES (3) | ES2275669T3 (cs) |
| GB (2) | GB2363987A (cs) |
| HU (4) | HU229797B1 (cs) |
| IL (1) | IL152306A0 (cs) |
| MA (1) | MA26892A1 (cs) |
| MX (3) | MXPA02010213A (cs) |
| MY (1) | MY129384A (cs) |
| NO (4) | NO332025B1 (cs) |
| NZ (1) | NZ521887A (cs) |
| PE (1) | PE20011227A1 (cs) |
| PL (3) | PL204213B1 (cs) |
| PT (3) | PT1276472E (cs) |
| SA (1) | SA01220062B1 (cs) |
| SI (2) | SI1719505T1 (cs) |
| SK (1) | SK284248B6 (cs) |
| TN (1) | TNSN01060A1 (cs) |
| WO (3) | WO2001078693A2 (cs) |
Families Citing this family (169)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| AU3409399A (en) * | 1999-03-05 | 2000-09-28 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| IL153705A0 (en) * | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| EP2298285A3 (en) | 2000-11-30 | 2011-07-27 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| PT1337239E (pt) * | 2000-11-30 | 2010-01-26 | Vectura Ltd | Partículas servindo à preparação de uma composição farmacêutica |
| WO2002043702A2 (en) † | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
| WO2002056948A1 (en) | 2001-01-17 | 2002-07-25 | Vectura Limited | An inhaler device |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
| US7931533B2 (en) | 2001-09-28 | 2011-04-26 | Igt | Game development architecture that decouples the game logic from the graphics logics |
| SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| EP1498116A1 (en) * | 2002-03-20 | 2005-01-19 | Hosokawa Micron Corporation | Method of manufacturing chemical-containing composite particles |
| FI116657B (fi) * | 2002-03-28 | 2006-01-31 | Focus Inhalation Oy | Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö |
| US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
| US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
| GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| ATE520405T1 (de) * | 2002-08-21 | 2011-09-15 | Norton Healthcare Ltd | Inhalationszusammensetzung |
| AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
| AU2004231342A1 (en) * | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| EP1643973A1 (en) * | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Pharmaceutical formulations comprising magnesium stearate |
| ES2243840T3 (es) | 2003-07-25 | 2005-12-01 | Ferring B.V. | Composicion farmaceutica de desmopresina como forma farmaceutica solida de dosificacion y metodo para la fabricacion de la misma. |
| CN1826099B (zh) * | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| WO2005025535A2 (en) * | 2003-09-15 | 2005-03-24 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
| SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| AU2004294889B2 (en) * | 2003-12-03 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Medical product containing tiotropium |
| US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| WO2005104712A2 (en) * | 2004-04-23 | 2005-11-10 | Cydex, Inc. | Dpi formulation containing sulfoalkyl ether cyclodextrin |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| KR20070119631A (ko) | 2005-02-10 | 2007-12-20 | 글락소 그룹 리미티드 | 사전-분류 기술을 이용한 락토오스 제조 공정 및 이로부터제조된 약제 제형 |
| JPWO2006095788A1 (ja) * | 2005-03-09 | 2008-08-14 | 小野薬品工業株式会社 | 粒子およびその粒子を含有する製剤 |
| MX2007012084A (es) * | 2005-03-30 | 2007-11-21 | Schering Corp | Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada. |
| TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0622818D0 (en) * | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1944018A1 (en) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| MX2009008582A (es) | 2007-02-11 | 2009-10-30 | Map Pharmaceuticals Inc | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. |
| EP2176251B1 (en) | 2007-07-21 | 2012-02-08 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof |
| EP2674417A3 (en) | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
| CA2711865A1 (en) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency |
| US8716308B2 (en) | 2008-01-11 | 2014-05-06 | Albany Molecular Research, Inc. | (1-azinone)-substituted pyridoindoles |
| EP2080508A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| EP2191821A1 (en) | 2008-11-26 | 2010-06-02 | CHIESI FARMACEUTICI S.p.A. | Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation |
| US8673931B2 (en) | 2009-01-26 | 2014-03-18 | Abraham Fisher | Bicyclic heterocyclic spiro compounds |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| PL3578169T3 (pl) | 2009-02-26 | 2024-09-02 | Glaxo Group Limited | Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol |
| EP2421514A2 (en) * | 2009-04-24 | 2012-02-29 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
| WO2011015289A1 (en) | 2009-08-04 | 2011-02-10 | Chiesi Farmaceutici S.P.A. | 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| EP2360147A1 (en) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
| MY162391A (en) | 2010-04-01 | 2017-06-15 | Chiesi Farm Spa | Process for preparing carrier particles for dry powders for inhalation |
| PL2560611T3 (pl) * | 2010-04-21 | 2018-05-30 | Chiesi Farmaceutici S.P.A. | Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych |
| ES2623799T3 (es) | 2010-04-30 | 2017-07-12 | Alexion Pharmaceuticals, Inc. | Anticuerpos anti-C5a y métodos para el uso de los anticuerpos |
| EP2575786B1 (en) | 2010-06-03 | 2017-11-15 | Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. | Process for dry powder formulations |
| PE20130282A1 (es) | 2010-06-22 | 2013-03-25 | Chiesi Farma Spa | Formulacion en polvo seca que comprende una droga antimuscarinica |
| MA34449B1 (fr) * | 2010-08-03 | 2013-08-01 | Chiesi Farma Spa | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase |
| US20130177651A1 (en) * | 2010-09-03 | 2013-07-11 | Pharmaterials Limited | Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler |
| US9642798B2 (en) | 2010-09-29 | 2017-05-09 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
| ES2704688T3 (es) | 2010-09-30 | 2019-03-19 | Chiesi Farm Spa | Uso de estearato de magnesio en formulaciones de polvo seco para inhalación |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
| TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
| TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
| EP2804583A1 (en) * | 2012-01-16 | 2014-11-26 | Mahmut Bilgic | Dry powder formulations comprising r-formoterol as active agent |
| WO2013109214A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Process for the preparation of dry powder formulations |
| WO2013109215A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Preparation of dry powder formulations comprising formoterol |
| JP6104282B2 (ja) | 2012-01-25 | 2017-03-29 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | コルチコステロイドとベータアドレナリン作用薬とを含んでなる吸入投与用の乾燥粉末製剤 |
| WO2013114374A1 (en) | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
| US20150136130A1 (en) | 2012-02-29 | 2015-05-21 | Pulmatrix, Inc. | Inhalable dry powders |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
| US10111957B2 (en) * | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US11052202B2 (en) | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2014208359B2 (en) | 2013-01-28 | 2018-04-26 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide |
| GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| ES2662847T3 (es) * | 2013-07-01 | 2018-04-10 | Arven Ilac Sanayi Ve Ticaret A.S. | Formulaciones novedosas de inhalación |
| PL3409270T3 (pl) * | 2013-07-11 | 2021-08-09 | Chiesi Farmaceutici S.P.A. | Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta- adrenergiczny do podawania wziewnego |
| EP3052092A2 (en) * | 2013-10-02 | 2016-08-10 | Vectura Limited | Method and apparatus |
| US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| EP2957552B1 (en) | 2014-06-16 | 2020-01-22 | Arven Ilac Sanayi Ve Ticaret A.S. | Vilanterol formulations |
| TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
| EP3166641B1 (en) | 2014-07-09 | 2018-09-12 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of formulations for inhalation |
| US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
| US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
| WO2016209208A1 (en) * | 2015-06-23 | 2016-12-29 | Schlumberger Canada Limited | Mobile proppant recognition |
| US11224594B2 (en) * | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
| DK3377108T3 (da) | 2015-11-16 | 2020-04-20 | Chiesi Farm Spa | Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum |
| HRP20211599T1 (hr) * | 2015-11-16 | 2022-01-07 | Chiesi Farmaceutici S.P.A. | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
| KR102697599B1 (ko) * | 2015-12-24 | 2024-08-23 | 필립모리스 프로덕츠 에스.에이. | 니코틴 입자 캡슐 |
| EP3463461A4 (en) | 2016-05-27 | 2020-05-20 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| US20190240194A1 (en) | 2016-08-31 | 2019-08-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| RU2742376C1 (ru) * | 2017-05-11 | 2021-02-05 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик |
| MA48620A (fr) | 2017-05-11 | 2021-04-28 | Chiesi Farm Spa | Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| EP3652210A1 (en) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| CN111107788B (zh) * | 2017-07-26 | 2023-12-19 | 深圳帧观德芯科技有限公司 | 具有空间扩展性x射线源的x射线成像系统 |
| EP4218813A3 (en) | 2017-07-27 | 2023-08-16 | Alexion Pharmaceuticals, Inc. | High concentration anti-c5 antibody formulations |
| WO2019060604A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
| WO2019060797A1 (en) | 2017-09-22 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | PROCESS FOR PRODUCING POWDERS FOR INHALING |
| CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| WO2019067708A1 (en) * | 2017-09-27 | 2019-04-04 | Teva Branded Pharmaceutical Products R&D, Inc. | METHOD FOR DECREASING PARTICLE SIZE |
| KR20240162603A (ko) | 2017-10-26 | 2024-11-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| JP7520725B2 (ja) | 2018-05-31 | 2024-07-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与 |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| KR20210071943A (ko) * | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
| EP3829641B1 (en) | 2018-07-27 | 2024-05-22 | Chiesi Farmaceutici S.p.A. | Novel carrier particles for dry powder formulations for inhalation |
| KR20210042412A (ko) | 2018-09-06 | 2021-04-19 | 주식회사 이노파마스크린 | 천식 또는 파킨슨병 치료를 위한 방법 및 조성물 |
| US12097329B2 (en) | 2018-10-30 | 2024-09-24 | Chiesi Farmaceutici S.P.A. | Apparatus to administer drugs to mechanically ventilated patients |
| CA3118282A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| CA3122989A1 (en) | 2018-12-10 | 2020-06-18 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| CN113412117B (zh) | 2018-12-12 | 2025-03-04 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| CA3138530A1 (en) | 2019-04-29 | 2020-11-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| BR112022004970A2 (pt) | 2019-09-24 | 2022-08-23 | Chiesi Farm Spa | Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| IL297538A (en) | 2020-04-24 | 2022-12-01 | Millennium Pharm Inc | Anti-cd19 antibodies and uses thereof |
| WO2021237109A1 (en) | 2020-05-22 | 2021-11-25 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
| CN112451509B (zh) * | 2020-12-19 | 2023-03-07 | 沈阳药科大学 | 一种川丁特罗吸入粉雾剂及其制备方法 |
| EP4320149A1 (en) | 2021-04-09 | 2024-02-14 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
| US20230111279A1 (en) | 2021-04-26 | 2023-04-13 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
| MX2023011712A (es) | 2021-04-26 | 2023-10-12 | Millennium Pharm Inc | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. |
| WO2023068382A2 (en) | 2021-10-20 | 2023-04-27 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| CN118475343A (zh) | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
| EP4452222A1 (en) | 2021-12-21 | 2024-10-30 | Chiesi Farmaceutici S.p.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| GB1381872A (en) | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
| GB1520247A (en) | 1974-08-10 | 1978-08-02 | Fisons Ltd | Pelletised medicament formulations |
| GB1571629A (en) | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
| US4349542A (en) * | 1979-06-08 | 1982-09-14 | National Research Development Corporation | Mixture containing active ingredient and dendritic crystalline sugar for tableting |
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| ATE94801T1 (de) | 1990-01-29 | 1993-10-15 | Ciba Geigy Ag | Verfahren und vorrichtung zur dosierung eines feinkoernigen pulvers. |
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| ATE204750T1 (de) | 1992-06-12 | 2001-09-15 | Teijin Ltd | Pharmazeutische zubereitung zur anwendung in den atemwegen |
| GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SE9700136D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6475462B1 (en) * | 1997-09-30 | 2002-11-05 | Mortimer Technology Holdings Limited | Process and apparatus for treating particulate matter |
| IL138153A0 (en) * | 1998-03-16 | 2001-10-31 | Inhale Therapeutic Syst | Methods and devices for delivering aerosolized active agents |
| PT1131059E (pt) | 1998-11-13 | 2003-07-31 | Jago Res Ag | Po seco para inalacao |
| GB9826783D0 (en) * | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
| AU3409399A (en) | 1999-03-05 | 2000-09-28 | Chiesi Farmaceutici S.P.A. | Improved powdery pharmaceutical compositions for inhalation |
| EP1666028B1 (en) * | 1999-10-29 | 2010-03-24 | Novartis AG | Dry powder compositions having improved dispersivity |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| IL153705A0 (en) * | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
-
2001
- 2001-04-11 PE PE2001000338A patent/PE20011227A1/es active IP Right Grant
- 2001-04-16 TN TNTNSN01060A patent/TNSN01060A1/fr unknown
- 2001-04-17 GB GB0109431A patent/GB2363987A/en not_active Withdrawn
- 2001-04-17 DK DK01931612T patent/DK1274406T3/da active
- 2001-04-17 AT AT07110708T patent/ATE513542T1/de active
- 2001-04-17 PT PT01921610T patent/PT1276472E/pt unknown
- 2001-04-17 KR KR1020027013929A patent/KR20030069047A/ko not_active Withdrawn
- 2001-04-17 EE EEP200200593A patent/EE05257B1/xx unknown
- 2001-04-17 HU HU0300593A patent/HU229797B1/hu unknown
- 2001-04-17 PT PT01931612T patent/PT1274406E/pt unknown
- 2001-04-17 CZ CZ20023437A patent/CZ301904B6/cs not_active IP Right Cessation
- 2001-04-17 PL PL358875A patent/PL204213B1/pl unknown
- 2001-04-17 EP EP01931612A patent/EP1274406B1/en not_active Expired - Lifetime
- 2001-04-17 WO PCT/EP2001/004338 patent/WO2001078693A2/en not_active Ceased
- 2001-04-17 IL IL15230601A patent/IL152306A0/xx unknown
- 2001-04-17 BR BR0110139-0A patent/BR0110139A/pt not_active Application Discontinuation
- 2001-04-17 SA SA01220062A patent/SA01220062B1/ar unknown
- 2001-04-17 EP EP01921610A patent/EP1276472B1/en not_active Revoked
- 2001-04-17 AU AU2001258343A patent/AU2001258343A1/en not_active Abandoned
- 2001-04-17 DK DK01921610T patent/DK1276472T3/da active
- 2001-04-17 HU HU1300117A patent/HU230464B1/hu unknown
- 2001-04-17 AU AU48581/01A patent/AU784719B2/en not_active Ceased
- 2001-04-17 SK SK1491-2002A patent/SK284248B6/sk not_active IP Right Cessation
- 2001-04-17 JP JP2001575995A patent/JP2003530425A/ja active Pending
- 2001-04-17 US US10/257,790 patent/US8182791B2/en not_active Expired - Fee Related
- 2001-04-17 DE DE60131265T patent/DE60131265T2/de not_active Revoked
- 2001-04-17 NZ NZ521887A patent/NZ521887A/en unknown
- 2001-04-17 CA CA2406201A patent/CA2406201C/en not_active Expired - Fee Related
- 2001-04-17 ES ES01921610T patent/ES2275669T3/es not_active Expired - Lifetime
- 2001-04-17 ES ES01931612T patent/ES2272473T3/es not_active Expired - Lifetime
- 2001-04-17 DK DK06017742.5T patent/DK1719505T3/da active
- 2001-04-17 HU HU0300499A patent/HU229270B1/hu unknown
- 2001-04-17 CA CA2405767A patent/CA2405767C/en not_active Expired - Lifetime
- 2001-04-17 DE DE60123031T patent/DE60123031T2/de not_active Expired - Lifetime
- 2001-04-17 EP EP06017742A patent/EP1719505B1/en not_active Expired - Lifetime
- 2001-04-17 EP EP07110708A patent/EP1829533B1/en not_active Revoked
- 2001-04-17 SI SI200131003T patent/SI1719505T1/sl unknown
- 2001-04-17 MX MXPA02010213A patent/MXPA02010213A/es active IP Right Grant
- 2001-04-17 AT AT01921610T patent/ATE348603T1/de active
- 2001-04-17 PL PL01358640A patent/PL358640A1/xx not_active Application Discontinuation
- 2001-04-17 PT PT06017742T patent/PT1719505E/pt unknown
- 2001-04-17 HU HU0300490A patent/HUP0300490A2/hu unknown
- 2001-04-17 AU AU48595/01A patent/AU4859501A/en not_active Abandoned
- 2001-04-17 PL PL359289A patent/PL204251B1/pl unknown
- 2001-04-17 CN CN01808256A patent/CN1424909A/zh active Pending
- 2001-04-17 MX MXPA02010212A patent/MXPA02010212A/es active IP Right Grant
- 2001-04-17 EP EP01921625A patent/EP1276473B1/en not_active Revoked
- 2001-04-17 CA CA002406119A patent/CA2406119C/en not_active Expired - Lifetime
- 2001-04-17 BR BR0110141-2A patent/BR0110141A/pt not_active Application Discontinuation
- 2001-04-17 AT AT01931612T patent/ATE339195T1/de active
- 2001-04-17 AT AT06017742T patent/ATE521340T1/de active
- 2001-04-17 EP EP10185445.3A patent/EP2272508B1/en not_active Expired - Lifetime
- 2001-04-17 DE DE60125344T patent/DE60125344T2/de not_active Expired - Lifetime
- 2001-04-17 MX MXPA02010218A patent/MXPA02010218A/es active IP Right Grant
- 2001-04-17 BR BR0110301-6A patent/BR0110301A/pt not_active Application Discontinuation
- 2001-04-17 WO PCT/GB2001/001732 patent/WO2001078694A2/en not_active Ceased
- 2001-04-17 GB GB0109432A patent/GB2363988A/en not_active Withdrawn
- 2001-04-17 AT AT01921625T patent/ATE377416T1/de not_active IP Right Cessation
- 2001-04-17 SI SI200130658T patent/SI1274406T1/sl unknown
- 2001-04-17 MY MYPI20011834A patent/MY129384A/en unknown
- 2001-04-17 US US10/257,368 patent/US6884794B2/en not_active Expired - Lifetime
- 2001-04-17 ES ES01921625T patent/ES2292576T3/es not_active Expired - Lifetime
- 2001-04-17 WO PCT/GB2001/001751 patent/WO2001078695A2/en not_active Ceased
- 2001-04-17 DZ DZ013315A patent/DZ3315A1/fr active
-
2002
- 2002-10-04 MA MA26851A patent/MA26892A1/fr unknown
- 2002-10-16 NO NO20024980A patent/NO332025B1/no not_active IP Right Cessation
- 2002-10-16 NO NO20024971A patent/NO20024971L/no not_active Application Discontinuation
- 2002-10-16 NO NO20024973A patent/NO342999B1/no not_active IP Right Cessation
-
2005
- 2005-03-08 US US11/073,625 patent/US7223748B2/en not_active Expired - Lifetime
-
2006
- 2006-11-28 CY CY20061101708T patent/CY1107315T1/el unknown
-
2011
- 2011-06-20 NO NO20110885A patent/NO336687B1/no not_active IP Right Cessation
-
2012
- 2012-04-25 US US13/455,277 patent/US20120308613A1/en not_active Abandoned
- 2012-09-28 JP JP2012217416A patent/JP2012255035A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332025B1 (no) | Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter | |
| ES2369923T3 (es) | Formulaciones farmacéuticas para inhaladores de polvo seco en forma de granulos duros. | |
| EP1158960B1 (en) | Modified carrier particles for use in dry powder inhalers | |
| HK1224619A1 (en) | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient | |
| HK1224619B (en) | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient | |
| HK1152895A (en) | Pharmaceutical formulations for dry powder inhalers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |